WASHINGTON (AP) - Federal prosecutors allege that Indian generic drugmaker Ranbaxy Laboratories deliberately misled the U.S. government about the quality of its low-cost medicines.
The Justice Department is demanding Ranbaxy turn over documents which it hopes will prove the company fabricated data to convince the U.S. government to approve its products.